Phase 1 Trial: EMP-012-1
This is an early-stage research study, known as a Phase 1 trial, called EMP-012-1. In studies like this, researchers are usually testing a new treatment or medicine for the first time in people. The main goal is to check its safety and how it works in the body. At this very initial stage, the organisation that reviews and approves health research, the Health Research Authority (HRA), has decided that all the detailed information about this specific trial, such as who can take part, what the treatment is, and what will happen during the study, won't be made public just yet. This is sometimes done to protect early research. Don't worry, all these details will be shared and available to everyone within 30 months after the study has finished.
At a glance
What is this study about?
This study, called EMP-012-1, is a 'Phase 1' clinical trial. Think of new medicines or treatments going through different stages of testing, like climbing a ladder. Phase 1 is the very first step on that ladder where a new treatment is tried in people. The main goals at this stage are usually to check if the treatment is safe, to see what dose works best, and to understand how the body handles it. It's not usually about whether the treatment cures a specific illness at this early point.
The Health Research Authority (HRA) is the organisation in the UK that looks closely at all health research studies to make sure they are ethical and safe for people taking part. For this particular study, the HRA has agreed that the full details of the trial, including specifics about the treatment, who can join, and what participants will experience, will not be published immediately. This isn't unusual for very early-stage research.
The good news is that these full details won't be hidden forever. They will be officially added to the study record and made public within 30 months after the entire trial has been completed. This delay allows researchers to gather initial information without revealing everything about their very early-stage work, but ensures transparency in the long run. So, while we don't have all the ins and outs right now, we know the information will become available in due course.
Key takeaways
- This is EMP-012-1, a very early-stage (Phase 1) clinical trial.
- The main goal is likely to check the safety of a new treatment.
- Full details about the treatment and who can join are not public yet.
- These details will be shared within 30 months after the trial ends.
- The study is open to all sexes, but other eligibility is unknown.
- Participation involves unconfirmed visits, assessments, and treatment.
Who may be eligible?
Unfortunately, at this very early stage of the study, the specific details about who can and cannot take part have not been made public yet. This means we don't have information on any particular health conditions, age ranges (beyond 'any to any'), or other medical criteria that might be important.
What we do know is that the study is open to people of all sexes. However, with the full details currently private, we cannot advise on any other specific requirements for joining.
Once the study has finished, within 30 months, all the information about who was eligible to take part, including any specific inclusion (who can join) and exclusion (who cannot join) criteria, will be made publicly available. Until then, we don't have the details to provide a clear eligibility checklist.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you of any age? (Specific age limits are unknown)
- Are you male, female, or unstated? (All sexes are included)
- Do you understand that full eligibility details are not yet public?
- Are you comfortable with the idea that specific health conditions for inclusion/exclusion are not known?
- Are you willing to wait for more information to be released after the study concludes?
What does participation involve?
As the full details of this early-stage study are not yet publicly known, we cannot explain exactly what taking part would involve. Generally, in a Phase 1 study, participants might expect to:
* Have several hospital visits for health check-ups, blood tests, and to receive the new treatment. * Take a new medication or treatment, possibly over a period of weeks or months. * Undergo frequent assessments to monitor their health and how their body reacts to the treatment. * Have a follow-up period after the treatment finishes to ensure they remain well.
The total duration of taking part can vary greatly in Phase 1 trials, from a few weeks to several months, followed by a monitoring period. However, for this specific study, these details are currently not available.
Potential risks and benefits
Locations (1)
- Medicines Evaluation Unit LimitedCity onlyManchester, England
Common questions
What is a 'Phase 1' trial?
It's the first stage of testing a new medicine or treatment in people, mainly to check if it's safe and how it works in the body.
When will more details about this study be available?
The full details will be made public within 30 months after the study has finished.
Why aren't the details public now?
For very early research, the Health Research Authority (HRA) sometimes allows details to be kept private initially, which can protect ongoing research work.
Can men and women take part?
Yes, the study is open to individuals of all sexes.
Will I get 'cured' if I join this study?
Phase 1 trials are mostly about safety and understanding the treatment, not usually about finding a cure at this early stage.
How to find out more
Michael Molyneaux
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.